galectin-3 antibody | knockout validation | Cedarlane Laboratories CL8942AP
DOI
//dx.doi.org/10.13070/ko.en.7.2212
Date
2017-03-18

This is a knockout-validated antibody summary, based on the publication "Myocardial Galectin-3 Expression Is Associated with Remodeling of the Pressure-Overloaded Heart and May Delay the Hypertrophic Response without Affecting Survival, Dysfunction, and Cardiac Fibrosis", as cited below [1]. Labome curates formal publications to compile a list of antibodies with unambiguous specificity within Validated Antibody Database (VAD).

Antibody information

Rat monoclonal IgG2a

Company: Cedarlane Laboratories

Antibody: galectin-3

Catalog number: CL8942AP

Summary: Rat monoclonal IgG2a against galectin-3 from plasma membrane glycoproteins from C57BL/6 mouse thioglycollate elicited peritoneal exudate. Reacts with human and mouse. Suitable for western blot, immunofluorescence, flow cytometry, immunohistochemistry (paraffin and frozen) and ELISA.

Validation Method

Immunohistochemistry

Sample

Heart sections from WT and galectin-3-KO mice. Hearts were excised, fixed in zinc formalin, and embedded in paraffin for sectioning.

Blocking agent

2% rabbit serum (Vectastain ELITE kit; Vector Laboratories Inc.)

Primary incubation

1:200 dilution.

Secondary incubation

Peroxidase-based technique with the Vectastain ELITE rat kit (Vector Laboratories Inc., Burlingame, CA).

Detection

Diaminobenzidine with nickel.

Figure

Please see Figure 2 in the article [1].

Clone note

The same clone (M3/38) is sold as BioLegend 125401, 125402, 125408, 125405, 125410, 125403, 125404, 125412, 125416; Santa Cruz Biotechnology sc-23938; LifeSpan Biosciences LS-C62616, LS-C62617, LS-C106169, LS-C106245, LS-C62936, LS-B9424; Abnova MAB12468; Invitrogen BMS1043; EMD Millipore MABT51; Cedarlanelabs CL8942AP.

References
  1. Frunza O, Russo I, Saxena A, Shinde A, Humeres C, Hanif W, et al. Myocardial Galectin-3 Expression Is Associated with Remodeling of the Pressure-Overloaded Heart and May Delay the Hypertrophic Response without Affecting Survival, Dysfunction, and Cardiac Fibrosis. Am J Pathol. 2016;186:1114-27 pubmed publisher